Phase 2 Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years old or older
- You must have signed a consent form agreeing to take part in the study
- You must be covered by a social security/health insurance system
- You must have Crohn's disease affecting the digestive tract that is considered "controlled" (mild symptoms based on a specific scoring system), diagnosed using clinical, imaging, or tissue tests for more than 3 months
- You must have had a colonoscopy within the last year that showed no ulcers in the rectum
- You must have a complex, long-lasting anal fistula (an abnormal tunnel near the back passage) with a limited number of openings (no more than two internal and three external)
- You must currently be receiving a combined treatment involving surgical drainage tubes and a specific type of medication called anti-TNF therapy, and this treatment must not have worked well enough after 6 months, while your Crohn's disease in the gut itself remains under control
Who may not be able to join:
- You do not wish to take part in the study
- You have tested positive for tuberculosis on a specific blood test called QuantiFERON
- You have had an organ transplant
- You have been diagnosed with cancer or a blood/lymph system cancer in the last five years
- You currently have an ongoing bacterial or viral infection
- You have a medical reason why you cannot have an MRI scan (confirm with trial site)
- You have a known allergy to Gadolinium (a substance used in MRI scans)
- You have a known allergy to Albumin (a protein)
- You have severe, end-stage failure of a major organ (such as the heart, liver, or kidneys)
- You are currently pregnant or breastfeeding
- You are a woman who could become pregnant but are not using reliable contraception for the entire duration of the study
- You are under a form of legal protection or guardianship that affects your ability to consent (confirm with trial site)
- You have previously been treated with a medicine called ALOFISEL®
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Etienne BUSCAIL, MD, Toulouse Hospital
Phone: 05 61 32 23 73
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
adverse events of grade ≥ 2 at 6 months; Efficacy of AdMSC by clinical evaluation at 6 months; Efficacy of AdMSC by radiological evaluation at 6 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.